Susquehanna International Group’s Avalo Therapeutics AVTX Stock Holding History

Susquehanna International Group’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.43M	Buy	163,000 +138,700	+571%	+$2.17M	﹤0.01%	5720
2025 Q4	$441K	Buy	24,300 +10,700	+79%	+$181K	﹤0.01%	9096
2025 Q3	$173K	Buy	+13,600	New	+$117K	﹤0.01%	11138
2022 Q2	–	Sell	-5	Closed	-$10K	–	12846
2022 Q1	$10K	Sell	5 -9	-64%	-$22.6K	﹤0.01%	12747
2021 Q4	$70K	Sell	14 -12	-46%	-$72K	﹤0.01%	12376
2021 Q3	$166K	Sell	26 -3	-10%	-$24.3K	﹤0.01%	11695
2021 Q2	$272K	Buy	29 +16	+123%	+$134K	﹤0.01%	10985
2021 Q1	$109K	Buy	+13	New	+$123K	﹤0.01%	11815

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Susquehanna International Group's AVTX Position: Q1 2026 in Review

Susquehanna International Group sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 210,994 shares — an estimated $3.3M sold.

Susquehanna International Group first reported a position in AVTX in Q1 2019 and held it in 15 quarters. The position peaked at $3.83M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

Susquehanna International Group reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
Susquehanna International Group sold 210,994 Avalo Therapeutics shares in Q1 2026, an estimated $3.3M.
Susquehanna International Group first reported a position in Avalo Therapeutics in Q1 2019 and held it in 15 quarters.
Susquehanna International Group's Avalo Therapeutics position peaked at $3.83M in Q4 2025.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.